Novavax is a late-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. The company's vaccine candidates, including its primary candidates, ResVax? and NanoFlu?, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. The company's product pipeline targets a variety of infectious diseases. The company is also developing immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company's primary adjuvant, Matrix-M?, has been shown to improve immune responses and was well-tolerated in multiple clinical trials.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.